Searched for
INDIA DRUG PRICING
India’s drug pricing policy must balance affordability, medicine availability and pharma industry growthThe Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...- India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: PharmexcilIndia's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...
- Cancer care can be cheaper: 6 steps to cut drug costsIndia has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...
- Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
- SC pulls up Centre over soaring medicine costsThe Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sande...
- Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Hospitals overcharge patients upto 700% on medicines while India makes some of the world’s lowest priced drugs: Centre admits to SCGovt has told Supreme Court that hospitals overcharging patients for medicines and medical consumables is a malpractice. Its affidavit cite...
- Sahajanand Medical Technologies shares list at 8% premium over IPO price on NSEThe Rs 475.48 crore IPO comprised an offer for sale (OFS) of 1.38 crore shares. Since the issue was entirely an OFS, the company will not r...
- Ashish Kacholia portfolio: Ace investor adds 3 new stocks, trims stake in 13 companies in Q2Ace investor Ashish Kacholia reshuffled his Rs 3,000 crore portfolio in Q2FY27, adding three stocks, increasing stakes in two companies and...
- Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in IndiaSanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to ...
- Sweet sellers face heat over shelf life rules ahead of DiwaliWatchdog agencies in states such as Uttar Pradesh and Uttarakhand are among those that have made this mandatory. The directive aims to help...
- NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. ...
- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
Load More
